VANCOUVER, BC, July 29, 2026
Victory Square Technologies Inc. has provided an update on Hydreight Technologies and its broader healthcare investment portfolio following recommendations from the U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) concerning several peptide-related bulk drug substances. Victory Square is Hydreight’s largest shareholder, holding approximately 44.5% of the company’s issued common shares, making the evolving regulatory landscape relevant to one of its significant healthcare investments. During meetings held July 23 and 24, 2026, the FDA advisory committee recommended that BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon be included on the Section 503A Bulks List, while Emideltide (DSIP) was not recommended. Importantly, the committee recommendations are non-binding and do not constitute FDA approval of the substances or any finished drug products. The FDA will determine whether to propose the substances for inclusion on the Section 503A Bulks List through its regulatory rulemaking process.
Hydreight Evaluates Evolving FDA Peptide Framework
The regulatory development is particularly relevant to Hydreight Technologies, a digital healthcare platform connecting healthcare providers, pharmacies and patients throughout the United States. Victory Square said Hydreight will continue monitoring the FDA regulatory process while evaluating potential opportunities in consultation with its clinical, pharmacy and legal partners. According to previously reported disclosures, Hydreight’s infrastructure includes more than 12,000 VSDHOne licenses sold, operations across all 50 U.S. states, a network exceeding 300 licensed physicians and more than 3,000 licensed nurses, alongside a nationwide pharmacy network. Its platform supports more than 45 physician-supervised treatment offerings spanning GLP-1 therapies, peptide-based treatments, hormone optimization, NAD+ therapies, IV wellness, sexual health and other personalized healthcare programs. Hydreight has also previously disclosed that peptide-based therapies including Sermorelin and Ipamorelin are offered through its physician-supervised platform. The latest committee recommendations therefore highlight an evolving regulatory environment that digital healthcare and pharmacy platforms must continue to evaluate carefully.
Insu Therapeutics Advances Peptide Drug Delivery Platform
Victory Square’s healthcare portfolio also includes an investment in Insu Therapeutics, a development-stage biotechnology company working on a proprietary buccal drug delivery platform for peptide and biologic molecules. The technology is being developed to deliver therapeutic molecules through the buccal mucosa inside the cheek, potentially providing an alternative to injectable administration and conventional oral dosage forms. Development objectives include creating a needle-free administration route, eliminating sharps disposal associated with injectable medicines and enabling drug delivery through the buccal mucosa rather than the gastrointestinal tract. The platform is intended to support multiple peptide and biologic molecules, although it remains subject to continued research, development, clinical evaluation and applicable regulatory requirements. Victory Square is also developing Pawsible Ventures, a companion animal health initiative focused on technology-enabled veterinary care, diagnostics, therapeutics and preventative health, further broadening the company’s exposure to healthcare innovation.
Advertisement
Victory Square Expands Healthcare Technology Investments
The FDA advisory committee recommendations arrive as Victory Square continues building investments spanning digital healthcare, healthcare infrastructure, drug delivery technology and companion animal health. The company provides portfolio businesses with capital, operational support, strategic guidance and industry relationships intended to support their development and growth. In Hydreight, Victory Square has substantial exposure to a nationwide digital healthcare infrastructure business, while Insu Therapeutics provides exposure to emerging peptide and biologic drug-delivery technologies. The company emphasized that the recent PCAC vote represents an advisory step rather than a final regulatory determination. FDA rulemaking will ultimately determine whether the recommended peptide-related bulk drug substances are added to the Section 503A Bulks List. As regulatory scrutiny of compounded medicines and peptide-related substances continues to evolve, the outcome could have implications for healthcare providers, pharmacies and digital platforms operating in this segment. For Victory Square, the development provides an important regulatory backdrop for Hydreight while underscoring the company’s broader strategy of investing in technology-enabled healthcare businesses. The next key development will be the FDA’s regulatory process following the advisory committee recommendations, while Hydreight continues assessing the implications for its healthcare platform and physician-supervised treatment ecosystem.
Source: Victory Square Technologies press release
